Zealand Pharma Strengthens Leadership with New Hire from Eli Lilly as Obesity Pipeline Expands

In a strategic move signaling its commitment to tackling obesity through innovative therapies, Zealand Pharma has announced the appointment of a former Eli Lilly executive, Chris Pashley. This transition comes as the biotech firm accelerates its efforts in developing treatments aimed at obesity, a growing global health concern.

Continue reading

Revolutionary Obesity Drug from Novo Nordisk Aims for Major Weight Loss Breakthrough

In a significant advancement in weight loss treatment, Novo Nordisk, the renowned pharmaceutical company behind the popular diabetes medication Ozempic, has introduced a new drug specifically designed to tackle obesity. This innovative drug, currently in clinical development, promises substantial weight loss results that could redefine obesity management and significantly impact the way overweight individuals approach weight loss.

Continue reading